Riskpilot← Back to searchSign inGet full accessTAFRE AS
ASActiveOrg 913294807Andebuveien 63, 3170 SemManufacture of pharmaceutical preparations · NACE 2120Est. 20145 employees
Revenue 2024
NOK 8,3M
+22% vs 2023
EBITDA margin
13.7%
+180% vs 2023
Equity ratio
49.7%
Financial strength
Net profit 2024
NOK 829K
+258% vs 2023
| Revenue | NOK 8,3M | +22% |
| EBITDA | NOK 1,1M | +180% |
| Net profit | NOK 829K | +258% |
| Total assets | NOK 4,6M | +49% |
| Equity | NOK 2,3M | +56% |
| Employees | 5 | — |
Legal name
TAFRE AS
Org number
913294807
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
26. februar 2014
Share capital
NOK 100 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Styrets leder alene.
Company purpose
Salg og distribusjon av medisinsk utstyr samt tilhørende virksomhet.
Address
Andebuveien 63, 3170 Sem
Phone
+4733331313
Email
post@tafre.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 654 | 1 071 | 2 026 | 2 333 | 3 234 | 3 847 | 6 202 | 7 380 | 7 626 | 6 779 | 8 272 |
| Staff expenses | −0 | −0 | −16 | −51 | −197 | −408 | −538 | −1 037 | −1 075 | −928 | −1 532 |
| EBITDA | 2 | −28 | −164 | 45 | 68 | 125 | 464 | 264 | 324 | 406 | 1 136 |
| Depreciation & amort. | −35 | −35 | −35 | −35 | −0 | −0 | −5 | −6 | −14 | −30 | −16 |
| EBIT | −33 | −63 | −199 | 10 | 68 | 125 | 459 | 257 | 310 | 376 | 1 121 |
| Net financials | −5 | −2 | −3 | −7 | −9 | −9 | 19 | −27 | −27 | −79 | −59 |
| Profit before tax | −38 | −66 | −202 | 3 | 59 | 115 | 440 | 231 | 283 | 296 | 1 062 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | 103 | 59 | 21 | 65 | 234 |
| Net profit | −38 | −66 | −202 | 3 | 59 | 115 | 338 | 172 | 262 | 231 | 829 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 390 | 440 | 483 | 690 | 876 | 979 | 1 809 | 2 503 | 2 694 | 3 103 | 4 633 |
| Equity | 2 | −63 | 94 | 97 | 356 | 471 | 809 | 981 | 1 243 | 1 475 | 2 303 |
| Long-term debt | 360 | 360 | 300 | 325 | 225 | 225 | 225 | 225 | 225 | 475 | 389 |
| Short-term debt | 27 | 143 | 89 | 268 | 295 | 283 | 775 | 1 297 | 1 225 | 1 154 | 1 940 |
| Total debt | 387 | 503 | 389 | 593 | 520 | 508 | 1 000 | 1 522 | 1 450 | 1 629 | 2 329 |
EBITDA margin
13.7%
This company
15.8%
Market median
-13% vs market
20142024
Equity ratio
49.7%
This company
38.2%
Market median
+30% vs market
20142024
Return on equity
36.0%
This company
18.4%
Market median
+96% vs market
20142024
Net profit margin
10.0%
This company
8.1%
Market median
+23% vs market
20142024
Asset turnover
1.79×
This company
1.12×
Market median
+60% vs market
20142024
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20142024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CT Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Fertiliteam As | Company | 83.3% | 83.3% | 2024 |
Allby Holding As | Company | 18.2% | 18.2% | 2023 |
| Individual | 16.7% | 16.7% | 2024 | |
| Individual | 13.6% | 13.6% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TAFRE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christel Taranger Freberg | Chief Executive Officer | 0 companies |
| Tom Roar Skillinghaug Andersen | Board of Directors | 0 companies |
| Jannicke Elisabeth Mølbach | Board of Directors | 0 companies |